Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

Inclusion Criteria: * Histological confirmation of adrenocortical carcinoma (ACC) based on either: i). Weiss Score of \>= 3 in patients who had earlier surgical resection OR ii). biopsy results compatible with ACC in the context of clinical setting highly suggestive of ACC (adrenal mass \> 4 cm invading surrounding organs or associated with distant metastases). * Locally advanced or metastatic disease not amenable to surgery with curative intent with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as determined by the investigator based on an assessment of all known disease sites by computerized tomography (CT) scan or magnetic resonance imaging (MRI) of chest/abdomen/pelvis within 28 days before the first dose of cabozantinib. In patients with intravenous (IV) contrast allergy or borderline renal function, CT without IV contrast or 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) CT may be used as clinically indicated. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Recovery to baseline or =\< grade 1 CTCAE v.4.0 from toxicities related to any prior treatments, unless adverse events (AEs) are clinically nonsignificant and/or stable on supportive therapy. * Life expectancy of at least 3 months. * Absolute neutrophil count (ANC) \>= 1500/mm\^3 without colony stimulating factor support (obtained within 28 days prior to the first dose of cabozantinib). * Platelets \>= 100,000/mm\^3 (obtained within 28 …